These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16178742)

  • 1. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
    Natarajan SR; Doherty JB
    Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
    Natarajan SR; Wisnoski DD; Thompson JE; O'Neill EA; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4400-4. PubMed ID: 16750629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.
    Natarajan SR; Wisnoski DD; Singh SB; Stelmach JE; O'Neill EA; Schwartz CD; Thompson CM; Fitzgerald CE; O'Keefe SJ; Kumar S; Hop CE; Zaller DM; Schmatz DM; Doherty JB
    Bioorg Med Chem Lett; 2003 Jan; 13(2):273-6. PubMed ID: 12482438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.
    Selness SR; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Devraj RV; Messing D; Schindler JF; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4059-65. PubMed ID: 21640588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
    Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.
    Liu L; Stelmach JE; Natarajan SR; Chen MH; Singh SB; Schwartz CD; Fitzgerald CE; O'Keefe SJ; Zaller DM; Schmatz DM; Doherty JB
    Bioorg Med Chem Lett; 2003 Nov; 13(22):3979-82. PubMed ID: 14592489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors.
    Chen MH; Fitzgerald P; Singh SB; O'Neill EA; Schwartz CD; Thompson CM; O'Keefe SJ; Zaller DM; Doherty JB
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2222-6. PubMed ID: 18316187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.
    Fitzgerald CE; Patel SB; Becker JW; Cameron PM; Zaller D; Pikounis VB; O'Keefe SJ; Scapin G
    Nat Struct Biol; 2003 Sep; 10(9):764-9. PubMed ID: 12897767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
    Adams JL; Boehm JC; Gallagher TF; Kassis S; Webb EF; Hall R; Sorenson M; Garigipati R; Griswold DE; Lee JC
    Bioorg Med Chem Lett; 2001 Nov; 11(21):2867-70. PubMed ID: 11597418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.
    Legos JJ; McLaughlin B; Skaper SD; Strijbos PJ; Parsons AA; Aizenman E; Herin GA; Barone FC; Erhardt JA
    Eur J Pharmacol; 2002 Jun; 447(1):37-42. PubMed ID: 12106800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
    Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
    Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
    Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors.
    Bolós J
    Mini Rev Med Chem; 2005 Sep; 5(9):857-68. PubMed ID: 16178727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
    Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
    Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.